Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer
Micro-Abstract The efficacy of cabazitaxel (CAB) after abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) is unknown. Because both affect the androgen receptor (AR) there is a concern about the activity of this sequence. We retrospectively demonstrated a prostate-spe...
Gespeichert in:
| Veröffentlicht in: | Clinical genitourinary cancer 2014-12, Vol.12 (6), p.428-432 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 432 |
|---|---|
| container_issue | 6 |
| container_start_page | 428 |
| container_title | Clinical genitourinary cancer |
| container_volume | 12 |
| creator | Sella, Avishay Sella, Tal Peer, Avivit Berger, Raanan Frank, Stephen Jay Gez, Eli Sharide, David Hayat, Henry Hanovich, Ekaterina Kovel, Svetlana Rosenbaum, Eli Neiman, Victoria Keizman, Daniel |
| description | Micro-Abstract The efficacy of cabazitaxel (CAB) after abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) is unknown. Because both affect the androgen receptor (AR) there is a concern about the activity of this sequence. We retrospectively demonstrated a prostate-specific antigen (PSA) response of 31.5%, partial response of 15.3%, and median survival of 8.2 months with CAB. CAB was active after AA and docetaxel in mCRPC. |
| doi_str_mv | 10.1016/j.clgc.2014.06.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1629964876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1558767314001104</els_id><sourcerecordid>1629964876</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-d65ba5eaa6fb7eede748f48381e9d1f3698633f9506a280fe9931baf0af1dc6f3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSNERf_AF-CAfOSSME4cJ5EQUrRQqFSpFRRxtCbOmHrJOovtrdhKfHcctnDgwMljz3tPnt9k2XMOBQcuX60LPX3VRQlcFCALgOZRdsK7qs1BtuXjVNd1mzeyqY6z0xDWAKLmDTzJjssapCxLfpL97HW0dzbu2WzYCge8txF_0MR6E8mzt7Omwx3dyPrBekzPsyPWL41I7OaWPG73zDp2jdGSi4F9sfE2hYWY1HZ2-UcKNkR0kV37Ofy2rdBp8k-zI4NToGcP51n2-fzdzepDfnn1_mLVX-ZaCBHzUdYD1oQozdAQjdSI1oi2ajl1IzeV7FpZVaZLU2HZgqGuq_iABtDwUUtTnWUvD7lbP3_fUYhqY4OmaUJH8y4oLsuuk6JtZJKWB6lOXw2ejNp6u0G_VxzUgl2t1YJdLdgVSJWwJ9OLh_zdsKHxr-UP5yR4fRBQmvLOkldBJ1aaRutJRzXO9v_5b_6x68k6q3H6RnsK63nnXeKnuAqlAvVpWfyydy4AOAdR_QKXK6qg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1629964876</pqid></control><display><type>article</type><title>Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Sella, Avishay ; Sella, Tal ; Peer, Avivit ; Berger, Raanan ; Frank, Stephen Jay ; Gez, Eli ; Sharide, David ; Hayat, Henry ; Hanovich, Ekaterina ; Kovel, Svetlana ; Rosenbaum, Eli ; Neiman, Victoria ; Keizman, Daniel</creator><creatorcontrib>Sella, Avishay ; Sella, Tal ; Peer, Avivit ; Berger, Raanan ; Frank, Stephen Jay ; Gez, Eli ; Sharide, David ; Hayat, Henry ; Hanovich, Ekaterina ; Kovel, Svetlana ; Rosenbaum, Eli ; Neiman, Victoria ; Keizman, Daniel</creatorcontrib><description>Micro-Abstract The efficacy of cabazitaxel (CAB) after abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) is unknown. Because both affect the androgen receptor (AR) there is a concern about the activity of this sequence. We retrospectively demonstrated a prostate-specific antigen (PSA) response of 31.5%, partial response of 15.3%, and median survival of 8.2 months with CAB. CAB was active after AA and docetaxel in mCRPC.</description><identifier>ISSN: 1558-7673</identifier><identifier>EISSN: 1938-0682</identifier><identifier>DOI: 10.1016/j.clgc.2014.06.007</identifier><identifier>PMID: 25066221</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Abiraterone Acetate ; Aged ; Aged, 80 and over ; Androgen receptor ; Androstenes - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy ; Docetaxel and Abiraterone failure ; Drug Resistance, Neoplasm - drug effects ; Hematology, Oncology and Palliative Medicine ; Humans ; Kaplan-Meier Estimate ; Male ; Metastatic castration-resistant prostate cancer ; Middle Aged ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Prostatic Neoplasms, Castration-Resistant - mortality ; Retrospective Studies ; Sequential therapy ; Taxoids - administration & dosage ; Urology</subject><ispartof>Clinical genitourinary cancer, 2014-12, Vol.12 (6), p.428-432</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-d65ba5eaa6fb7eede748f48381e9d1f3698633f9506a280fe9931baf0af1dc6f3</citedby><cites>FETCH-LOGICAL-c444t-d65ba5eaa6fb7eede748f48381e9d1f3698633f9506a280fe9931baf0af1dc6f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25066221$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sella, Avishay</creatorcontrib><creatorcontrib>Sella, Tal</creatorcontrib><creatorcontrib>Peer, Avivit</creatorcontrib><creatorcontrib>Berger, Raanan</creatorcontrib><creatorcontrib>Frank, Stephen Jay</creatorcontrib><creatorcontrib>Gez, Eli</creatorcontrib><creatorcontrib>Sharide, David</creatorcontrib><creatorcontrib>Hayat, Henry</creatorcontrib><creatorcontrib>Hanovich, Ekaterina</creatorcontrib><creatorcontrib>Kovel, Svetlana</creatorcontrib><creatorcontrib>Rosenbaum, Eli</creatorcontrib><creatorcontrib>Neiman, Victoria</creatorcontrib><creatorcontrib>Keizman, Daniel</creatorcontrib><title>Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer</title><title>Clinical genitourinary cancer</title><addtitle>Clin Genitourin Cancer</addtitle><description>Micro-Abstract The efficacy of cabazitaxel (CAB) after abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) is unknown. Because both affect the androgen receptor (AR) there is a concern about the activity of this sequence. We retrospectively demonstrated a prostate-specific antigen (PSA) response of 31.5%, partial response of 15.3%, and median survival of 8.2 months with CAB. CAB was active after AA and docetaxel in mCRPC.</description><subject>Abiraterone Acetate</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgen receptor</subject><subject>Androstenes - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Chemotherapy</subject><subject>Docetaxel and Abiraterone failure</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Metastatic castration-resistant prostate cancer</subject><subject>Middle Aged</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Prostatic Neoplasms, Castration-Resistant - mortality</subject><subject>Retrospective Studies</subject><subject>Sequential therapy</subject><subject>Taxoids - administration & dosage</subject><subject>Urology</subject><issn>1558-7673</issn><issn>1938-0682</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxSNERf_AF-CAfOSSME4cJ5EQUrRQqFSpFRRxtCbOmHrJOovtrdhKfHcctnDgwMljz3tPnt9k2XMOBQcuX60LPX3VRQlcFCALgOZRdsK7qs1BtuXjVNd1mzeyqY6z0xDWAKLmDTzJjssapCxLfpL97HW0dzbu2WzYCge8txF_0MR6E8mzt7Omwx3dyPrBekzPsyPWL41I7OaWPG73zDp2jdGSi4F9sfE2hYWY1HZ2-UcKNkR0kV37Ofy2rdBp8k-zI4NToGcP51n2-fzdzepDfnn1_mLVX-ZaCBHzUdYD1oQozdAQjdSI1oi2ajl1IzeV7FpZVaZLU2HZgqGuq_iABtDwUUtTnWUvD7lbP3_fUYhqY4OmaUJH8y4oLsuuk6JtZJKWB6lOXw2ejNp6u0G_VxzUgl2t1YJdLdgVSJWwJ9OLh_zdsKHxr-UP5yR4fRBQmvLOkldBJ1aaRutJRzXO9v_5b_6x68k6q3H6RnsK63nnXeKnuAqlAvVpWfyydy4AOAdR_QKXK6qg</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Sella, Avishay</creator><creator>Sella, Tal</creator><creator>Peer, Avivit</creator><creator>Berger, Raanan</creator><creator>Frank, Stephen Jay</creator><creator>Gez, Eli</creator><creator>Sharide, David</creator><creator>Hayat, Henry</creator><creator>Hanovich, Ekaterina</creator><creator>Kovel, Svetlana</creator><creator>Rosenbaum, Eli</creator><creator>Neiman, Victoria</creator><creator>Keizman, Daniel</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141201</creationdate><title>Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer</title><author>Sella, Avishay ; Sella, Tal ; Peer, Avivit ; Berger, Raanan ; Frank, Stephen Jay ; Gez, Eli ; Sharide, David ; Hayat, Henry ; Hanovich, Ekaterina ; Kovel, Svetlana ; Rosenbaum, Eli ; Neiman, Victoria ; Keizman, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-d65ba5eaa6fb7eede748f48381e9d1f3698633f9506a280fe9931baf0af1dc6f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Abiraterone Acetate</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgen receptor</topic><topic>Androstenes - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Chemotherapy</topic><topic>Docetaxel and Abiraterone failure</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Metastatic castration-resistant prostate cancer</topic><topic>Middle Aged</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Prostatic Neoplasms, Castration-Resistant - mortality</topic><topic>Retrospective Studies</topic><topic>Sequential therapy</topic><topic>Taxoids - administration & dosage</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sella, Avishay</creatorcontrib><creatorcontrib>Sella, Tal</creatorcontrib><creatorcontrib>Peer, Avivit</creatorcontrib><creatorcontrib>Berger, Raanan</creatorcontrib><creatorcontrib>Frank, Stephen Jay</creatorcontrib><creatorcontrib>Gez, Eli</creatorcontrib><creatorcontrib>Sharide, David</creatorcontrib><creatorcontrib>Hayat, Henry</creatorcontrib><creatorcontrib>Hanovich, Ekaterina</creatorcontrib><creatorcontrib>Kovel, Svetlana</creatorcontrib><creatorcontrib>Rosenbaum, Eli</creatorcontrib><creatorcontrib>Neiman, Victoria</creatorcontrib><creatorcontrib>Keizman, Daniel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genitourinary cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sella, Avishay</au><au>Sella, Tal</au><au>Peer, Avivit</au><au>Berger, Raanan</au><au>Frank, Stephen Jay</au><au>Gez, Eli</au><au>Sharide, David</au><au>Hayat, Henry</au><au>Hanovich, Ekaterina</au><au>Kovel, Svetlana</au><au>Rosenbaum, Eli</au><au>Neiman, Victoria</au><au>Keizman, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer</atitle><jtitle>Clinical genitourinary cancer</jtitle><addtitle>Clin Genitourin Cancer</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>12</volume><issue>6</issue><spage>428</spage><epage>432</epage><pages>428-432</pages><issn>1558-7673</issn><eissn>1938-0682</eissn><abstract>Micro-Abstract The efficacy of cabazitaxel (CAB) after abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) is unknown. Because both affect the androgen receptor (AR) there is a concern about the activity of this sequence. We retrospectively demonstrated a prostate-specific antigen (PSA) response of 31.5%, partial response of 15.3%, and median survival of 8.2 months with CAB. CAB was active after AA and docetaxel in mCRPC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25066221</pmid><doi>10.1016/j.clgc.2014.06.007</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1558-7673 |
| ispartof | Clinical genitourinary cancer, 2014-12, Vol.12 (6), p.428-432 |
| issn | 1558-7673 1938-0682 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1629964876 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Abiraterone Acetate Aged Aged, 80 and over Androgen receptor Androstenes - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy Docetaxel and Abiraterone failure Drug Resistance, Neoplasm - drug effects Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Male Metastatic castration-resistant prostate cancer Middle Aged Prostate-Specific Antigen - blood Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Retrospective Studies Sequential therapy Taxoids - administration & dosage Urology |
| title | Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A30%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activity%20of%20Cabazitaxel%20After%20Docetaxel%20and%20Abiraterone%20Acetate%20Therapy%20in%20Patients%20With%20Castration-Resistant%20Prostate%20Cancer&rft.jtitle=Clinical%20genitourinary%20cancer&rft.au=Sella,%20Avishay&rft.date=2014-12-01&rft.volume=12&rft.issue=6&rft.spage=428&rft.epage=432&rft.pages=428-432&rft.issn=1558-7673&rft.eissn=1938-0682&rft_id=info:doi/10.1016/j.clgc.2014.06.007&rft_dat=%3Cproquest_cross%3E1629964876%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1629964876&rft_id=info:pmid/25066221&rft_els_id=1_s2_0_S1558767314001104&rfr_iscdi=true |